SG11202004097RA - Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method - Google Patents
Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic methodInfo
- Publication number
- SG11202004097RA SG11202004097RA SG11202004097RA SG11202004097RA SG11202004097RA SG 11202004097R A SG11202004097R A SG 11202004097RA SG 11202004097R A SG11202004097R A SG 11202004097RA SG 11202004097R A SG11202004097R A SG 11202004097RA SG 11202004097R A SG11202004097R A SG 11202004097RA
- Authority
- SG
- Singapore
- Prior art keywords
- diagnostic
- expression
- cancer
- inhibitor
- active ingredient
- Prior art date
Links
- 238000000034 method Methods 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000004480 active ingredient Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2527/00—Reactions demanding special reaction conditions
- C12Q2527/125—Specific component of sample, medium or buffer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
- C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017216747 | 2017-11-09 | ||
| PCT/JP2018/041758 WO2019093502A1 (en) | 2017-11-09 | 2018-11-09 | Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004097RA true SG11202004097RA (en) | 2020-06-29 |
Family
ID=66438467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004097RA SG11202004097RA (en) | 2017-11-09 | 2018-11-09 | Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12253515B2 (en) |
| EP (1) | EP3719124A4 (en) |
| JP (1) | JP7376873B2 (en) |
| KR (1) | KR102715821B1 (en) |
| CN (1) | CN111315882B (en) |
| AU (1) | AU2018364001A1 (en) |
| CA (1) | CA3082006A1 (en) |
| IL (1) | IL274456B2 (en) |
| SG (1) | SG11202004097RA (en) |
| TW (1) | TWI816712B (en) |
| WO (1) | WO2019093502A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI780046B (en) | 2016-05-10 | 2022-10-11 | 國立大學法人東京醫科齒科大學 | Expression suppressors of pro-inflammatory factors, screening method of effective ingredients thereof, expression cassettes usuful to the method, diagnostic agents and disgnostic methods |
| US20230272402A1 (en) * | 2018-12-25 | 2023-08-31 | Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences | Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof |
| CN113499440B (en) * | 2021-08-23 | 2023-04-28 | 大连医科大学 | Application of reagent for down regulating RBMS1 expression in preparation of medicine for treating lung cancer |
| CN114191556B (en) * | 2022-01-11 | 2023-04-28 | 大连医科大学 | Application of reagent for knocking down RBMS1 in preparation of medicine for treating triple negative breast cancer |
| CN114605499B (en) * | 2022-04-07 | 2023-06-23 | 华中科技大学同济医学院附属协和医院 | A kind of polypeptide RIP-18 that can antagonize the RNA binding activity of RBSM1 protein and its application |
| KR20240125190A (en) * | 2023-02-10 | 2024-08-19 | 한국과학기술원 | Biomarker for colorectal cancer diagnosis, and diagnosis method using thereof |
| CN116574684B (en) * | 2023-03-07 | 2024-04-02 | 西安电子科技大学 | Functionalized monocyte/macrophage carrier, drug delivery system, preparation method and application of scavenger-type living cell anti-tumor metastasis |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1432724A4 (en) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| WO2006083477A2 (en) | 2005-01-07 | 2006-08-10 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| NZ544432A (en) * | 2005-12-23 | 2009-07-31 | Pacific Edge Biotechnology Ltd | Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS |
| US8217037B2 (en) | 2006-04-07 | 2012-07-10 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers |
| US8598333B2 (en) * | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
| MX2009003362A (en) * | 2006-09-28 | 2009-06-08 | Schering Corp | Use of pegylated il-10 to treat cancer. |
| JP5176035B2 (en) * | 2006-10-06 | 2013-04-03 | 愛知県 | Composition for cancer treatment using DREF as molecular target |
| EP2123752A4 (en) | 2006-12-18 | 2010-08-11 | Kyowa Hakko Kirin Co Ltd | Novel nucleic acid |
| AU2008335922A1 (en) * | 2007-12-11 | 2009-06-18 | Bayer Intellectual Property Gmbh | Oxazolidinones for the treatment and/or prophylaxis of heart failure |
| JP2009159869A (en) * | 2007-12-28 | 2009-07-23 | Univ Of Occupational & Environmental Health Japan | Cancer cell growth inhibition method, growth inhibitor and screening method |
| KR101589554B1 (en) | 2008-01-03 | 2016-02-01 | 코넬 리서치 파운데이션 인코포레이티드 | Glycosylated protein expression in prokaryotes |
| WO2009089548A2 (en) * | 2008-01-11 | 2009-07-16 | H. Lee Moffitt Cancer & Research Institute, Inc. | Malignancy-risk signature from histologically normal breast tissue |
| US20110053804A1 (en) | 2008-04-03 | 2011-03-03 | Sloan-Kettering Institute For Cancer Research | Gene Signatures for the Prognosis of Cancer |
| US8969005B2 (en) | 2010-03-28 | 2015-03-03 | The Trustees Of The University Of Pennsylvania | Gene targets associated with amyotrophic lateral sclerosis and methods of use thereof |
| US20130274128A1 (en) | 2010-09-21 | 2013-10-17 | The Regents Of The University Of Califorina | Gene expression in n-cadherin overexpressing prostate cancers and their controls |
| GB201016690D0 (en) * | 2010-10-05 | 2010-11-17 | Jenkins Paul | Method of detecting cancer |
| EP3597761B1 (en) | 2011-03-09 | 2025-05-07 | Richard G. Pestell | Prostate cancer cell lines, gene signatures and uses thereof |
| EP2861765B1 (en) | 2012-06-15 | 2019-01-23 | Progenity, Inc. | Methods of detecting diseases or conditions |
| US9994908B2 (en) | 2013-03-14 | 2018-06-12 | Abbott Molecular Inc. | Materials and methods for assessment of colorectal adenoma |
| JP2014236717A (en) | 2013-06-10 | 2014-12-18 | 学校法人立命館 | Inhibitors of endogenous cox-2 antisense rna and its use and screening methods therefor |
| US10264976B2 (en) | 2014-12-26 | 2019-04-23 | The University Of Akron | Biocompatible flavonoid compounds for organelle and cell imaging |
| KR20170132332A (en) | 2015-04-03 | 2017-12-01 | 난트바이오사이언스 인코포레이티드 | Mutant K-RAS Target Methods and Compositions |
| TWI780046B (en) * | 2016-05-10 | 2022-10-11 | 國立大學法人東京醫科齒科大學 | Expression suppressors of pro-inflammatory factors, screening method of effective ingredients thereof, expression cassettes usuful to the method, diagnostic agents and disgnostic methods |
-
2018
- 2018-11-09 SG SG11202004097RA patent/SG11202004097RA/en unknown
- 2018-11-09 EP EP18876883.2A patent/EP3719124A4/en active Pending
- 2018-11-09 AU AU2018364001A patent/AU2018364001A1/en not_active Abandoned
- 2018-11-09 WO PCT/JP2018/041758 patent/WO2019093502A1/en not_active Ceased
- 2018-11-09 TW TW107139918A patent/TWI816712B/en active
- 2018-11-09 CA CA3082006A patent/CA3082006A1/en active Pending
- 2018-11-09 US US16/762,227 patent/US12253515B2/en active Active
- 2018-11-09 JP JP2019552415A patent/JP7376873B2/en active Active
- 2018-11-09 KR KR1020207016429A patent/KR102715821B1/en active Active
- 2018-11-09 CN CN201880072534.1A patent/CN111315882B/en active Active
- 2018-11-09 IL IL274456A patent/IL274456B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3719124A1 (en) | 2020-10-07 |
| KR20200080309A (en) | 2020-07-06 |
| JP7376873B2 (en) | 2023-11-09 |
| TWI816712B (en) | 2023-10-01 |
| KR102715821B1 (en) | 2024-10-10 |
| CA3082006A1 (en) | 2019-05-16 |
| JPWO2019093502A1 (en) | 2021-02-25 |
| EP3719124A4 (en) | 2021-09-01 |
| US12253515B2 (en) | 2025-03-18 |
| US20200355672A1 (en) | 2020-11-12 |
| AU2018364001A1 (en) | 2020-06-25 |
| IL274456A (en) | 2020-06-30 |
| CN111315882A (en) | 2020-06-19 |
| IL274456B1 (en) | 2024-04-01 |
| WO2019093502A1 (en) | 2019-05-16 |
| IL274456B2 (en) | 2024-08-01 |
| CN111315882B (en) | 2024-09-24 |
| TW202018090A (en) | 2020-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274456A (en) | Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method | |
| EP4501932A3 (en) | Kras g12c inhibitors | |
| ZA202202932B (en) | Fxia inhibitors and preparation method therefor and pharmaceutical use thereof | |
| HK1252693A1 (en) | Inhibitors of egfr and methods of use thereof | |
| IL273664A (en) | Fill-finish assemblies and related methods | |
| IL259711A (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
| IL324103A (en) | Medical device packaging and related methods | |
| IL272446A (en) | Substituted penta- fused hexa-heterocyclic compounds, preparation method therefor, drug combination and use thereof | |
| SG11201707284PA (en) | Kv1.3 inhibitors and their medical application | |
| EP3518754A4 (en) | Blood pressure apparatus using active materials and related methods | |
| EP3687546A4 (en) | Compositions and methods for treating heart disease via redirected t cell immunotherapies | |
| IL273339A (en) | Griseofulvin compound and pharmaceutical use thereof | |
| SG11202004292PA (en) | Medicine for tissue regeneration, and preparation method therefor | |
| IL273955B2 (en) | Delayed release deferiprone tablets and methods of using the same | |
| PT3721718T (en) | Three-layered capsule composed of non-hydrogenated fat, and method for manufacturing same | |
| GB2582521B (en) | Preserved tissue products and related methods | |
| GB2578712B (en) | Apparatus and methods for the transdermal delivery of active agents | |
| GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof | |
| IL262794A (en) | Expression inhibitor of inflammation promoting factor, screening method for active ingredient thereof, expression cassette useful for said method, diagnostic agent and diagnosis method | |
| EP3347022A4 (en) | Pharmaceutical composition including dutasteride and capsule formulation comprising the same | |
| ZA201908090B (en) | Pharmaceutical composition and method for preparing same | |
| EP3253734A4 (en) | Glucosylceramide synthase inhibitors and therapeutic methods using the same | |
| IL268865A (en) | Product and method for the treatment of bioprosthetic tissues | |
| EP3704485A4 (en) | Diagnostic and therapeutic methods for type 2 diabetes | |
| ZA201705676B (en) | Kv1.3 inhibitors and their medical application |